CSL (Germany)

Recent papers from CSL (Germany)

1. Long-term prophylactic treatment and related real-world outcomes of patients with hereditary angioedema in Germany: A retrospective analysis of German claims and medical chart dataWorld Allergy Organization Journal · 2026
2. Real‐World Outcomes of Prophylaxis With rIX‐FP in Germany: A Prospective, Non‐Interventional Study in Haemophilia BHaemophilia · 2026
3. Abstract Number: Esoc2026a1661 Arteriolosclerosis and Cerebral Amyloid Angiopathy Co-Exist in Different Portions of the Same Vessels—a Novel Methodological Approach Using AI Digital Pathology and Single-Vessel AnalysisEuropean Stroke Journal · 2026
4. Garadacimab for the long-term prophylaxis of hereditary angioedema.2026
5. APOE ‐mediated sex differences in microvascular pathology and AD‐associated proteinopathies in the medial temporal lobeAlzheimer s & Dementia · 2026
6. Comparing Real-World Outcomes of Prophylaxis with Extended Half-life Factor IX (rIX-FP vs. rFIXFc and N9-GP) for Haemophilia B: An Analysis of Medical Chart Data from GermanyAdvances in Therapy · 2025
7. Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 studyMolecular Therapy — Methods & Clinical Development · 2025
8. Relationship between cerebral small vessel disease and proteinopathies in the medial temporal lobeActa Neuropathologica Communications · 2025
9. Characterization of recombinant Factor IX fusion proteins enabling subcutaneous administrationJournal of Thrombosis and Haemostasis · 2024
10. A 360-degree perspective on adeno-associated virus (AAV)-based gene therapy for haemophilia: Insights from the physician, the nurse and the patientOrphanet Journal of Rare Diseases · 2024
11. A multi-stakeholder collaborative approach to awareness, education and support needed in the haemophilia gene therapy patient journey – a report on insights from a European patient advisory boardThe Journal of Haemophilia Practice · 2024
12. Gene therapy for haemophilia A and B, from basic principles to clinical implementation: An illustrated reviewHaemophilia · 2023
13. Limited access to liver transplantation and TIPS despite high mortality, healthcare resource use and costs of cirrhosis in GermanyLiver International · 2023
14. Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapyBlood Advances · 2022
15. Clinical, economic, and health‐related quality of life burden associated with von Willebrand disease in adults and children: Systematic and targeted literature reviewsHaemophilia · 2022
16. Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviewsEuropean Respiratory Review · 2022
17. Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP)Journal of Neurology · 2020
18. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International AnalysisAdvances in Therapy · 2020
19. Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII‐SingleChain and other common rFVIII products in GermanyEuropean Journal Of Haematology · 2019
20. Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiencyInternational Immunopharmacology · 2018